{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:49:03Z","timestamp":1774550943601,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13555-025-01364-8","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T15:31:38Z","timestamp":1740756698000},"page":"763-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-050X","authenticated-orcid":false,"given":"Fabrizio","family":"Martora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Battista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"Suppl 1","key":"1364_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/exd.14338","volume":"30","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021;30(Suppl 1):8\u201317. https:\/\/doi.org\/10.1111\/exd.14338.","journal-title":"Exp Dermatol"},{"issue":"7","key":"1364_CR2","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3390\/ijms23073753","volume":"23","author":"A Markota \u010cagalj","year":"2022","unstructured":"Markota \u010cagalj A, Marinovi\u0107 B, Bukvi\u0107Mokos Z. New and emerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci. 2022;23(7):3753. https:\/\/doi.org\/10.3390\/ijms23073753.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1364_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/medicina59040801","volume":"59","author":"F Martora","year":"2023","unstructured":"Martora F, Scalvenzi M, Ruggiero A, Potestio L, Battista T, Megna M. Hidradenitis suppurativa and JAK inhibitors: a review of the published literature. Medicina (Kaunas). 2023;59(4):801. https:\/\/doi.org\/10.3390\/medicina59040801.","journal-title":"Medicina (Kaunas)"},{"key":"1364_CR4","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.2147\/CCID.S418748","volume":"16","author":"F Martora","year":"2023","unstructured":"Martora F, Scalvenzi M, Battista T, et al. Guselkumab, risankizumab, and tildrakizumab in the management of hidradenitis suppurativa: a review of existing trials and real-life data. Clin Cosmet Investig Dermatol. 2023;16:2525\u201336. https:\/\/doi.org\/10.2147\/CCID.S418748.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"1364_CR5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase\u00a02, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279\u201388. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2905.","journal-title":"JAMA Dermatol"},{"issue":"10443","key":"1364_CR6","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase\u00a03 trials. Lancet. 2024;403(10443):2504\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(24)00101-6.","journal-title":"Lancet"},{"key":"1364_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19921","author":"C Ure\u00f1a-Paniego","year":"2024","unstructured":"Ure\u00f1a-Paniego C, Haselgruber S, Soto-Moreno A, Cuenca-Barrales C, Arias-Santiago S, Molina-Leyva A. Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: lessons and pitfalls in a real-world setting. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.19921.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1364_CR8","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1111\/ajd.14339","volume":"65","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, Pons-Benavent M, Fern\u00e1ndez-Crehuet P, et al. Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: an ambispective observational study. Australa J Dermatol. 2024;65(7):e198\u2013202.","journal-title":"Australa J Dermatol"},{"issue":"5","key":"1364_CR9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.13185","volume":"83","author":"S Glatt","year":"2017","unstructured":"Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991\u20131001. https:\/\/doi.org\/10.1111\/bcp.13185.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1364_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/14740338.2023.2218086","volume":"22","author":"A Ruggiero","year":"2023","unstructured":"Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;22(5):355\u201362. https:\/\/doi.org\/10.1080\/14740338.2023.2218086.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1364_CR11","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","volume":"65","author":"C Schlapbach","year":"2011","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, Hunger RE. Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2010.07.010.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1364_CR12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","volume":"76","author":"\u0141 Matusiak","year":"2017","unstructured":"Matusiak \u0141, Szcz\u0119ch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76(4):670\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.042.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1364_CR13","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","volume":"139","author":"E Witte-H\u00e4ndel","year":"2019","unstructured":"Witte-H\u00e4ndel E, Wolk K, Tsaousi A, et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol. 2019;139(6):1294\u2013305. https:\/\/doi.org\/10.1016\/j.jid.2018.11.018.","journal-title":"J Invest Dermatol"},{"key":"1364_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CCID.S449367","volume":"17","author":"F Martora","year":"2024","unstructured":"Martora F, Marasca C, Cacciapuoti S, et al. Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52-week real-life study. Clin Cosmet Investig Dermatol. 2024;17:159\u201366. https:\/\/doi.org\/10.2147\/CCID.S449367.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"1364_CR15","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.jid.2024.05.015","volume":"144","author":"CA Maronese","year":"2024","unstructured":"Maronese CA, Valenti M, Moltrasio C, et al. Paradoxical psoriasis: an updated review of clinical features, pathogenesis, and treatment options. J Invest Dermatol. 2024;144(11):2364\u201376.","journal-title":"J Invest Dermatol"},{"issue":"10378","key":"1364_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week\u00a016 and week\u00a052 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase\u00a03 trials. Lancet. 2023;401(10378):747\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(23)00022-3.","journal-title":"Lancet"},{"issue":"12","key":"1364_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15866","volume":"35","author":"L Burzi","year":"2022","unstructured":"Burzi L, Repetto F, Ribero S, Mastorino L, Quaglino P, Dapavo P. Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: real-life experience and therapeutic response to other biological drugs. Dermatol Ther. 2022;35(12):e15866. https:\/\/doi.org\/10.1111\/dth.15866.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1364_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2024;20(5):525\u201345. https:\/\/doi.org\/10.1080\/1744666X.2023.2298356.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"1364_CR19","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1111\/ced.15306","volume":"47","author":"F Martora","year":"2022","unstructured":"Martora F, Marasca C, Battista T, Fabbrocini G, Ruggiero A. Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: \u201cEvaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa.\u201d Clin Exp Dermatol. 2022;47(11):2026\u20138.","journal-title":"Clin Exp Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01364-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01364-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01364-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:04:06Z","timestamp":1741939446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01364-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1364"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01364-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fabrizio Martora, Teresa Battista and Matteo Megna have nothing to declare. Luca Potestio is an Editorial Board member of Dermatology and Therapy. Luca Potestio was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Written informed consent for publication of their details was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}